Amarin | AMRN - Cost Of Sales


Amarin reported $26.05M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
Amarin USD 26.05M 1.41M Dec/2025
AstraZeneca USD -204M 3.48B Mar/2026
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Halozyme Therapeutics USD 108.75M 6.6M Mar/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Ionis Pharmaceuticals USD 3M 5M Mar/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
Novartis USD 3.46B 83M Mar/2026